Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TAS2R8 | Q9NYW2 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13971234 | 0.85 | ALDH1A1 (0.51) | MAPTKMT2AALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL14096157 | 0.82 | ALDH1A1 (0.49) | MAPTKMT2AALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL14096171 | 0.79 | ALDH1A1 (0.52) | MAPTKMT2AALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL4366369 | 0.76 | ALDH1A1 (0.76) | MAPTKMT2AALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL13956787 | 0.74 | RAB9A (0.52) | MAPTKMT2AALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL14096162 | 0.74 | ALDH1A1 (0.47) | MAPTKMT2AALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL14096159 | 0.74 | ALDH1A1 (0.53) | MAPTKMT2AALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL14096158 | 0.72 | ALDH1A1 (0.51) | MAPTKMT2AALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL14096169 | 0.71 | ALDH1A1 (0.52) | MAPTKMT2AALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL14096174 | 0.71 | ALDH1A1 (0.50) | MAPTKMT2AALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476686-B2 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-01-13 | — | — | US | claimed |
| US-20060014836-A1 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | CHEN DAWEI | 2006-01-19 | — | — | US | claimed |
| US-20040138205-A1 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | claimed |
| US-7476686-B2 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476686-B2 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-7094807-B2 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060014836-A1 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | CHEN DAWEI | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138205-A1 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | NAT1, PIGS, TPMT | MAPT 3454/4885KMT2A 2216/4885ALDH1A1 310/4885 |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | RNASE1, SARS1, EIF2AK2 | MAPT 4038/4885KMT2A 4579/4885ALDH1A1 2930/4885 |
| US-20060014836-A1 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | NAT1, PIGS, SLC10A1 | MAPT 3752/4885KMT2A 1703/4885ALDH1A1 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.